Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.32 USD | 0.00% | +23.42% | -51.71% |
06-07 | Brookline Capital Initiates SAB Biotherapeutics With Buy Rating, $8 Price Target | MT |
05-30 | SAB Biotherapeutics, Inc. Announces Change of Chief Financial Officer | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-51.71% | 30.64M | |
+18.35% | 125B | |
+14.11% | 108B | |
-6.80% | 23.64B | |
+2.39% | 22.39B | |
-12.11% | 17.78B | |
-41.64% | 16.43B | |
-14.86% | 16.34B | |
+0.25% | 13.56B | |
+25.00% | 11.59B |
- Stock Market
- Equities
- SABS Stock
- News SAB Biotherapeutics, Inc.
- SAB Biotherapeutics Stock Surges After FDA Breakthrough Designation of Influenza Drug Candidate